Posts Tagged ‘wanderment’

VF betaAR

November 3, 2010

A new variant of Virta-Flaneurazine, VF betaAR, has been successfully developed. It is produced from the skin secretions of bio- engineered and programmed hybrid Bufo toads. When areas of these toads are touched, the resulting reaction causes a wandering viewer to see things appearing from virtual worlds and other sources on the Internet. This appears to be an integrated and compelling conscious experience. This perception can be simultaneously viewed on an iPhone or Android device using Layars or other augmented reality software.

Because of the surprising success of our first test at MoMA, October 9, we will be entering a wider human test phase November 14 at BETA Spaces 2010 in Bushwick, Brooklyn (NY). The drug tests will be part of an art program, Bushwick AR Intervention. Though the parameters of the effects are somewhat limited at this point, this appears to be a very important step towards complete integration.

Advertisements

New Pill Design: Confusion and Facade Affinity

July 5, 2008

The new pill designs have arrived at the clinic also. We are now working on experiments with the proper dosage. It appears that our initial dosages are problematic. They produce two side effects that impede long-term wanderment variability. One is best described as confusion or disorientation. This causes the user to move in more limited areas and engage in crisscrossing or backtracking (See figure 1 below). The second effect can only be described as an affinity or fixation for the walls of buildings. In these cases the user seems to walk towards building facades and then, looking into windows, moves back and forth along them repeatedly (See figure 2 below). While this shows a consistency with aspects flâneurism such as window shopping or voyeurism,  it will also lead to less adventurous walks which are also desirable. We will be conducting more precise experiments with respected dosage shortly since this will be such an important part of the user’s experience. The issue is most likely related to code repeats and higher user rates of serotonin turnover, The figures below track these walks from the SL minimap aerial view.

              figure 1: confusion                     figure 2: facade affinity

New Pill Drives

July 2, 2008


The new external pill drives arrived recently. The new design combines a more carefully controlled delivery system together with a more “upbeat” color scheme. We are hoping this will address the “recreational” use issue as well as the recent identification of the widespread pathology of WDD or Wanderlust Deficit Disorder. We think this look expresses the essence of “wanderment“.

Wanderlust Deficit Disorder

June 20, 2008

MEMO #2008-06-20_032

To: Dr. willpap

From: Dr. johncraigfreeman

Re: Wanderlust Deficit Disorder

This is an internal memo intended for your eyes only. Please keep its contents confidential.

Given the disastrous results of the latest mice trials, the parent company and our investors have recommended a change of course in our research. They have asked us to consider redeveloping VF to target the lucrative recreational pharmaceutical market. In order to do this successfully, a malady must be identified, or created as the case may be, which VF can be reasonably seen to remedy.

After careful consideration. I propose that we focus on Wanderlust Deficit Disorder (WDD). We know that VF has shown promise in getting even the most flaccid internet addicts up and active, even if that activity is aimless or misdirected.

Internet Addiction

The parent company’s marketing department and our lobby consulting team agree that WDD could constitute a sizable market in coming years.

We have been asked to indicate this change of direction by changing the appearance of VF to include a more “happy-go-lucky” color scheme and sexier graphics.

Virta-Flaneurazine-SL, Midterm Report

March 11, 2008
The four-member team working on Virta-Flaneurazine-SL began its work in the fall of 2007 by isolating and analyzing the Virta-Flaneurazine-SL molecule and building the clinic in Second Life. Both of these endeavors have been successful. Reports on both areas follow.
 
VF Pill 01
 
Virta-Flaneurazine-SL Molecule:
Mass spectrometry suggests that the Virta-Flaneurazine-SL (VF) molecule resembles Lysergic acid diethylamide in many respects but with an extra molecular structure attached similar to 3-Mercaptopropionic Acid (3-MPA). 3-MPA is known to produce symptoms of disorientation. Presumably this accounts for the combined symptoms of wanderment and hallucination reported by patients. The results of our analysis of the VF molecule makes us confidant that we might now be able to dispel some of the misconceptions of composition that have previously circulated.
VF Molecule 01
 
VF Molecule 02 
 
Prograchemistry:
A number of the hallucinatory effects of VF have been programmatically discovered and can be rather easily triggered using both internal and external scripting. In the process of this research, the experience of “tunneling” was discovered to be a recurrent symptom. This means that at times patients perceive themselves moving down a tunnel or into a spiral. Searching into his own past, Dr* JC Freeman, realized a recurring attraction to the notion of mazes or labyrinths, while Dr* WD Pappenheimer remembered painting numerous spirals early in his teenage years.
VF Hallucination 01
The wanderment prograchemistry has also been well charted. The auto-body programming compulsion to wander randomly and aimlessly has been isolated and written. The problem of understanding means for auto-teleportation has been overcome through a series of assays and is now a usable. This prograchemistry represents mostly the external portion of the two-part drug. The further understanding and mastery of creating a long-term multi-variant wander excursion, responsive to individual patients experience, represents the challenge of future work in this area. The capability to translate programming to cross-platform technologies will also be addressed at the final stages of the research.
VF Hallucination 02
Virta-Flaneurazine-SL Clinic:
Finally, the in-world construction of the clinic is proceeding as planned and most of lab equipment has been delivered. The clinic has a furnished waiting area, situationist reading materials, a front counter, a good supply of medication, an exam room and necessary medical charts and equipment.
VF Clinic 01
This will be the location for in-world patient reception, recruiting, interviews, exams and distribution of the in-world dosage of the trial VF and placebo. Clinical study forms are being prepared and submitted for review and approval. 
VF Clinic 02
When completed the administration of the trial will ensure that patients clearly understand the nature of their participation as well as provide the data, which might influence the patient’s response to the trial.
Finally, plans are being drafted for the deployment of the out-world mobile clinic, consisting of a standing hospital curtain, two interview chairs, transit files and a data projection of patients’ experiences. The out-world mobile clinics will be important points for initiating and continuing patient relationships.
 VF Clinic 03